Cargando…
Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
Non‐Hodgkin lymphoma can occur concurrently with chronic phase‐chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second‐generation tyrosine kinase inhibitors and rituximab‐CHOP for patients newly diagnosed with CML and non‐Hodgkin lymphoma is effective for both diseases...
Autores principales: | Takeyasu, Yuki, Satake, Atsushi, Azuma, Yoshiko, Tsubokura, Yukie, Yoshimura, Hideaki, Hotta, Masaaki, Nakanishi, Takahisa, Fujita, Shinya, Nakaya, Aya, Ito, Tomoki, Nomura, Shosaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715580/ https://www.ncbi.nlm.nih.gov/pubmed/29225854 http://dx.doi.org/10.1002/ccr3.1253 |
Ejemplares similares
-
Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
por: Nakaya, Aya, et al.
Publicado: (2016) -
Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
por: Nakaya, Aya, et al.
Publicado: (2018) -
Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017) -
Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017) -
Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
por: Nakaya, Aya, et al.
Publicado: (2017)